NicOx, Merck deal

NicOx and Merck said they will use a new approach for nitric oxide (NO) donation as part of a revised 2006 deal after discontinuing further development of the deal's original NO-donating compounds. The companies said Phase I data of the compounds, which were focused on hypertension, did not meet the criteria to move into Phase II testing (see BioCentury, March 27, 2006). ...